ZA200303381B - Combination of gaba agonists and sorbitol dehydrogenase inhibitors. - Google Patents
Combination of gaba agonists and sorbitol dehydrogenase inhibitors. Download PDFInfo
- Publication number
- ZA200303381B ZA200303381B ZA200303381A ZA200303381A ZA200303381B ZA 200303381 B ZA200303381 B ZA 200303381B ZA 200303381 A ZA200303381 A ZA 200303381A ZA 200303381 A ZA200303381 A ZA 200303381A ZA 200303381 B ZA200303381 B ZA 200303381B
- Authority
- ZA
- South Africa
- Prior art keywords
- alkyl
- pyrimidin
- optionally substituted
- hydroxy
- piperazin
- Prior art date
Links
- 239000003477 4 aminobutyric acid receptor stimulating agent Substances 0.000 title claims description 29
- 108010009384 L-Iditol 2-Dehydrogenase Proteins 0.000 title description 2
- 102100026974 Sorbitol dehydrogenase Human genes 0.000 title description 2
- 239000003112 inhibitor Substances 0.000 title description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 258
- -1 vinylenyicarbonyi Chemical group 0.000 claims description 151
- 125000001153 fluoro group Chemical group F* 0.000 claims description 132
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 97
- 229910052739 hydrogen Inorganic materials 0.000 claims description 91
- 239000001257 hydrogen Substances 0.000 claims description 91
- 229910052799 carbon Inorganic materials 0.000 claims description 76
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 75
- 125000003545 alkoxy group Chemical group 0.000 claims description 72
- 229940002612 prodrug Drugs 0.000 claims description 61
- 239000000651 prodrug Substances 0.000 claims description 61
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 46
- 125000005843 halogen group Chemical group 0.000 claims description 41
- 150000001875 compounds Chemical class 0.000 claims description 40
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 31
- 150000003839 salts Chemical class 0.000 claims description 31
- 125000001424 substituent group Chemical group 0.000 claims description 30
- 125000004076 pyridyl group Chemical group 0.000 claims description 28
- 239000008194 pharmaceutical composition Substances 0.000 claims description 24
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 19
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 18
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 16
- 125000005466 alkylenyl group Chemical group 0.000 claims description 16
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 16
- 125000002757 morpholinyl group Chemical group 0.000 claims description 16
- 125000004193 piperazinyl group Chemical group 0.000 claims description 16
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 16
- 229920006395 saturated elastomer Polymers 0.000 claims description 16
- 125000000335 thiazolyl group Chemical group 0.000 claims description 16
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims description 15
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 15
- 125000002541 furyl group Chemical group 0.000 claims description 15
- 125000002971 oxazolyl group Chemical group 0.000 claims description 15
- 125000003386 piperidinyl group Chemical group 0.000 claims description 15
- 125000001544 thienyl group Chemical group 0.000 claims description 15
- 125000002947 alkylene group Chemical group 0.000 claims description 14
- 229910052757 nitrogen Chemical group 0.000 claims description 14
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 13
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 10
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
- 125000001624 naphthyl group Chemical group 0.000 claims description 10
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 claims description 10
- 241000124008 Mammalia Species 0.000 claims description 9
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 9
- 229910052717 sulfur Inorganic materials 0.000 claims description 9
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 8
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 8
- 125000002393 azetidinyl group Chemical group 0.000 claims description 8
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 8
- 125000005956 isoquinolyl group Chemical group 0.000 claims description 8
- ZJQHPWUVQPJPQT-UHFFFAOYSA-N muscimol Chemical group NCC1=CC(=O)NO1 ZJQHPWUVQPJPQT-UHFFFAOYSA-N 0.000 claims description 8
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 8
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 8
- 239000011593 sulfur Chemical group 0.000 claims description 8
- 208000002249 Diabetes Complications Diseases 0.000 claims description 7
- 206010012655 Diabetic complications Diseases 0.000 claims description 7
- 125000002785 azepinyl group Chemical group 0.000 claims description 7
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 7
- 229960002870 gabapentin Drugs 0.000 claims description 7
- 150000002431 hydrogen Chemical class 0.000 claims description 7
- 125000002883 imidazolyl group Chemical group 0.000 claims description 7
- 229960001233 pregabalin Drugs 0.000 claims description 7
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 claims description 7
- 125000005493 quinolyl group Chemical group 0.000 claims description 7
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 claims description 6
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 claims description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 6
- 125000002619 bicyclic group Chemical group 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 6
- 125000005842 heteroatom Chemical group 0.000 claims description 6
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 6
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 239000001301 oxygen Substances 0.000 claims description 6
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 6
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims description 6
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 6
- 150000003254 radicals Chemical class 0.000 claims description 6
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 6
- PBJUNZJWGZTSKL-MRXNPFEDSA-N tiagabine Chemical compound C1=CSC(C(=CCCN2C[C@@H](CCC2)C(O)=O)C2=C(C=CS2)C)=C1C PBJUNZJWGZTSKL-MRXNPFEDSA-N 0.000 claims description 6
- 125000001425 triazolyl group Chemical group 0.000 claims description 6
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 claims description 5
- 229960000623 carbamazepine Drugs 0.000 claims description 5
- 229960001848 lamotrigine Drugs 0.000 claims description 5
- 229960002036 phenytoin Drugs 0.000 claims description 5
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 5
- 229960001918 tiagabine Drugs 0.000 claims description 5
- 229960004394 topiramate Drugs 0.000 claims description 5
- PJDFLNIOAUIZSL-UHFFFAOYSA-N vigabatrin Chemical compound C=CC(N)CCC(O)=O PJDFLNIOAUIZSL-UHFFFAOYSA-N 0.000 claims description 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 4
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 claims description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims description 4
- 229960000794 baclofen Drugs 0.000 claims description 4
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 4
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 4
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims description 4
- 125000001041 indolyl group Chemical group 0.000 claims description 4
- 125000002950 monocyclic group Chemical group 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
- 125000004043 oxo group Chemical group O=* 0.000 claims description 4
- 229960002752 progabide Drugs 0.000 claims description 4
- IBALRBWGSVJPAP-HEHNFIMWSA-N progabide Chemical compound C=1C(F)=CC=C(O)C=1C(=N/CCCC(=O)N)/C1=CC=C(Cl)C=C1 IBALRBWGSVJPAP-HEHNFIMWSA-N 0.000 claims description 4
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 4
- 125000005554 pyridyloxy group Chemical group 0.000 claims description 4
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 4
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 4
- 125000004588 thienopyridyl group Chemical group S1C(=CC2=C1C=CC=N2)* 0.000 claims description 4
- 125000004306 triazinyl group Chemical group 0.000 claims description 4
- 229960005318 vigabatrin Drugs 0.000 claims description 4
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 claims description 3
- 125000005153 alkyl sulfamoyl group Chemical group 0.000 claims description 3
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 3
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims description 3
- 229960004181 riluzole Drugs 0.000 claims description 3
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 claims description 3
- 229960000604 valproic acid Drugs 0.000 claims description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
- 125000003342 alkenyl group Chemical group 0.000 claims description 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 2
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 2
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 claims description 2
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 claims description 2
- 239000004305 biphenyl Substances 0.000 claims description 2
- 235000010290 biphenyl Nutrition 0.000 claims description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 2
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 claims description 2
- NLUNLVTVUDIHFE-UHFFFAOYSA-N cyclooctylcyclooctane Chemical group C1CCCCCCC1C1CCCCCCC1 NLUNLVTVUDIHFE-UHFFFAOYSA-N 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 2
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 2
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 claims description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 2
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 2
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 claims description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 2
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 2
- 125000003282 alkyl amino group Chemical group 0.000 claims 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 claims 1
- 101150088095 RTM2 gene Proteins 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims 1
- 125000006085 pyrrolopyridyl group Chemical group 0.000 claims 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 14
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 13
- 229940123659 Sorbitol dehydrogenase inhibitor Drugs 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 102000005915 GABA Receptors Human genes 0.000 description 4
- 108010005551 GABA Receptors Proteins 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 206010007749 Cataract diabetic Diseases 0.000 description 3
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 3
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 3
- 208000032781 Diabetic cardiomyopathy Diseases 0.000 description 3
- 208000008960 Diabetic foot Diseases 0.000 description 3
- 206010063547 Diabetic macroangiopathy Diseases 0.000 description 3
- 206010054044 Diabetic microangiopathy Diseases 0.000 description 3
- 206010012689 Diabetic retinopathy Diseases 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 201000009101 diabetic angiopathy Diseases 0.000 description 3
- 201000007025 diabetic cataract Diseases 0.000 description 3
- 208000033679 diabetic kidney disease Diseases 0.000 description 3
- 108010060511 4-Aminobutyrate Transaminase Proteins 0.000 description 2
- 102100035923 4-aminobutyrate aminotransferase, mitochondrial Human genes 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 101150023881 agl11 gene Proteins 0.000 description 2
- 239000002249 anxiolytic agent Substances 0.000 description 2
- 230000000949 anxiolytic effect Effects 0.000 description 2
- 229940005530 anxiolytics Drugs 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000011885 synergistic combination Substances 0.000 description 2
- CSDSSGBPEUDDEE-UHFFFAOYSA-N 2-formylpyridine Chemical compound O=CC1=CC=CC=N1 CSDSSGBPEUDDEE-UHFFFAOYSA-N 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- KNAHARQHSZJURB-UHFFFAOYSA-N Propylthiouracile Chemical compound CCCC1=CC(=O)NC(=S)N1 KNAHARQHSZJURB-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 description 1
- 125000005090 alkenylcarbonyl group Chemical group 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000573 anti-seizure effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229940064790 dilantin Drugs 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 229940084457 gabitril Drugs 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940072170 lamictal Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 229940072228 neurontin Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 210000005215 presynaptic neuron Anatomy 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 229940090016 tegretol Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940035305 topamax Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25006900P | 2000-11-30 | 2000-11-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200303381B true ZA200303381B (en) | 2004-04-30 |
Family
ID=22946187
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200303381A ZA200303381B (en) | 2000-11-30 | 2003-04-30 | Combination of gaba agonists and sorbitol dehydrogenase inhibitors. |
Country Status (38)
| Country | Link |
|---|---|
| US (1) | US6544998B2 (de) |
| EP (1) | EP1337271B1 (de) |
| JP (1) | JP2004514699A (de) |
| KR (1) | KR20030059290A (de) |
| CN (1) | CN1477975A (de) |
| AP (1) | AP2001002360A0 (de) |
| AR (1) | AR031431A1 (de) |
| AT (1) | ATE281181T1 (de) |
| AU (1) | AU2002215159A1 (de) |
| BG (1) | BG107774A (de) |
| BR (1) | BR0115783A (de) |
| CA (1) | CA2430298A1 (de) |
| CR (1) | CR6964A (de) |
| CZ (1) | CZ20031399A3 (de) |
| DE (1) | DE60106968T2 (de) |
| DO (1) | DOP2001000289A (de) |
| EA (1) | EA200300432A1 (de) |
| EC (1) | ECSP034624A (de) |
| EE (1) | EE200300248A (de) |
| ES (1) | ES2230378T3 (de) |
| HR (1) | HRP20030420A2 (de) |
| HU (1) | HUP0302160A3 (de) |
| IL (1) | IL155704A0 (de) |
| IS (1) | IS6786A (de) |
| MA (1) | MA26964A1 (de) |
| MX (1) | MXPA03004870A (de) |
| NO (1) | NO20032441L (de) |
| OA (1) | OA12534A (de) |
| PA (1) | PA8534101A1 (de) |
| PE (1) | PE20020597A1 (de) |
| PL (1) | PL365927A1 (de) |
| PT (1) | PT1337271E (de) |
| SK (1) | SK6192003A3 (de) |
| SV (1) | SV2003000751A (de) |
| TN (1) | TNSN01169A1 (de) |
| UY (1) | UY27042A1 (de) |
| WO (1) | WO2002043762A2 (de) |
| ZA (1) | ZA200303381B (de) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100491282B1 (ko) | 1996-07-24 | 2005-05-24 | 워너-램버트 캄파니 엘엘씨 | 통증 치료용 이소부틸가바 및 그의 유도체 |
| US6992109B1 (en) * | 1999-04-08 | 2006-01-31 | Segal Catherine A | Method for the treatment of incontinence |
| US7022678B2 (en) * | 2001-03-30 | 2006-04-04 | Warner-Lambert Company | Pregabalin lactose conjugates |
| SK286227B6 (sk) * | 2001-05-25 | 2008-05-06 | Warner-Lambert Company Llc | Kvapalná farmaceutická kompozícia obsahujúca analóg GABA a spôsob jej prípravy a použitie |
| CA2451267A1 (en) * | 2002-12-13 | 2004-06-13 | Warner-Lambert Company Llc | Pharmaceutical uses for alpha2delta ligands |
| KR20050036195A (ko) * | 2003-10-15 | 2005-04-20 | 고재영 | 신규한 망막병증 치료제 조성물 |
| US8007827B2 (en) * | 2004-04-02 | 2011-08-30 | Impax Laboratories, Inc. | Pharmaceutical dosage forms having immediate release and/or controlled release properties |
| CA2560995A1 (en) * | 2004-04-02 | 2005-10-20 | Impax Laboratories, Inc. | Controlled release dosage for gaba receptor agonist |
| US20050220873A1 (en) * | 2004-04-02 | 2005-10-06 | Chien-Hsuan Han | Pharmaceutical dosage forms having immediate and controlled release properties that contain a GABAB receptor agonist |
| US20050226927A1 (en) * | 2004-04-02 | 2005-10-13 | Impax Laboratories, Inc. | Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a GABAB receptor agonist |
| GB0420831D0 (en) | 2004-09-17 | 2004-10-20 | Glaxo Group Ltd | Novel compounds |
| ES2528674T3 (es) | 2005-02-17 | 2015-02-11 | Astellas Pharma Inc. | Piperidina y carboxilatos de piperacina como inhibidores de FAAH |
| GB0513553D0 (en) * | 2005-07-01 | 2005-08-10 | Fond D Amico Per La Ricerca Su | Rab3a |
| DK2142529T3 (da) | 2007-04-27 | 2014-02-10 | Purdue Pharma Lp | Trpv1-antagonister og anvendelser deraf |
| JP5452494B2 (ja) * | 2007-10-09 | 2014-03-26 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | ベンフォチアミンと１または２種以上の医薬活性剤とを含む神経因性の疼痛状態の処置のための医薬組成物 |
| SG176464A1 (en) | 2008-05-09 | 2011-12-29 | Agency Science Tech & Res | Diagnosis and treatment of kawasaki disease |
| JP5815552B2 (ja) | 2009-12-08 | 2015-11-17 | ケース ウェスタン リザーブ ユニバーシティＣａｓｅ Ｗｅｓｔｅｒｎｒｅｓｅｒｖｅ Ｕｎｉｖｅｒｓｉｔｙ | 眼疾患を治療する化合物および方法 |
| DK2621282T3 (da) * | 2010-09-28 | 2020-05-04 | Univ California | Gaba-agonister i behandlingen af forstyrrelser forbundet med metabolisk syndrom og gaba-kombinationer i behandling eller profylakse af type i diabetes |
| CA2837178C (en) | 2011-06-22 | 2016-09-20 | Purdue Pharma L.P. | Trpv1 antagonists including dihydroxy substituent and uses thereof |
| US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| EP3955936A1 (de) | 2019-04-17 | 2022-02-23 | COMPASS Pathfinder Limited | Behandlung von depression und anderen verschiedenen störungen mit psilocybin |
| JP2022531466A (ja) * | 2019-05-07 | 2022-07-06 | ユニバーシティ オブ マイアミ | 遺伝性ニューロパチーおよび関連障害の処置および検出 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2409754A (en) | 1946-10-22 | Method for obtaining hydantoins | ||
| CH449645A (de) | 1963-07-09 | 1968-01-15 | Ciba Geigy | Verfahren zur Herstellung neuer Aminosäuren |
| CH427803A (de) | 1963-12-06 | 1967-01-15 | Geigy Ag J R | Verfahren zur Herstellung eines neuen Isoxazolderivates |
| DE2460891C2 (de) * | 1974-12-21 | 1982-09-23 | Gödecke AG, 1000 Berlin | 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
| US3960927A (en) | 1975-03-18 | 1976-06-01 | Richardson-Merrell Inc. | Olefinic derivatives of amino acids |
| FR2319338A1 (fr) * | 1975-08-01 | 1977-02-25 | Synthelabo | Nouveaux derives de a- phenyl benzylideniques des acides amines, leur preparation et les medicaments qui en contiennent |
| DK153787C (da) | 1979-06-01 | 1989-01-16 | Wellcome Found | Analogifremgangsmaade til fremstilling af substituerede 3,5-diamino-6-phenyl-1,2,4-triaziner og alfa-cyanobenzyliden-aminoguanidinforbindelser til anvendelse som mellemprodukter herved |
| FR2492258A1 (fr) * | 1980-10-17 | 1982-04-23 | Pharmindustrie | Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole |
| US4513006A (en) | 1983-09-26 | 1985-04-23 | Mcneil Lab., Inc. | Anticonvulsant sulfamate derivatives |
| DK288385D0 (da) | 1985-06-26 | 1985-06-26 | Novo Industri As | Aminosyrederivater |
| US6197819B1 (en) | 1990-11-27 | 2001-03-06 | Northwestern University | Gamma amino butyric acid analogs and optical isomers |
| KR950703539A (ko) * | 1992-09-28 | 1995-09-20 | 알렌 제이. 스피겔 | 당뇨병 합병증 치료용 치환된 피리미딘(substituted pyrimidines for control or diabetic complications) |
| AU3503300A (en) * | 1999-02-24 | 2000-09-14 | Regents Of The University Of California, The | Gaba receptors mediate inhibition of t cell responses |
| DE60009777T2 (de) * | 1999-04-01 | 2004-08-19 | Pfizer Products Inc., Groton | Verbindung für Behandlung und Vorsorge bei Diabetes |
| EP1185275A1 (de) * | 1999-04-01 | 2002-03-13 | Pfizer Products Inc. | Aminopyrimidine als sorbitdehydrogenasehemmer |
-
2001
- 2001-11-19 PT PT01983739T patent/PT1337271E/pt unknown
- 2001-11-19 WO PCT/IB2001/002213 patent/WO2002043762A2/en not_active Application Discontinuation
- 2001-11-19 EA EA200300432A patent/EA200300432A1/ru unknown
- 2001-11-19 CA CA002430298A patent/CA2430298A1/en not_active Abandoned
- 2001-11-19 ES ES01983739T patent/ES2230378T3/es not_active Expired - Lifetime
- 2001-11-19 EP EP01983739A patent/EP1337271B1/de not_active Expired - Lifetime
- 2001-11-19 PL PL01365927A patent/PL365927A1/xx not_active Application Discontinuation
- 2001-11-19 OA OA1200300142A patent/OA12534A/en unknown
- 2001-11-19 CN CNA018195946A patent/CN1477975A/zh active Pending
- 2001-11-19 KR KR10-2003-7007237A patent/KR20030059290A/ko not_active Application Discontinuation
- 2001-11-19 CZ CZ20031399A patent/CZ20031399A3/cs unknown
- 2001-11-19 JP JP2002545732A patent/JP2004514699A/ja not_active Withdrawn
- 2001-11-19 HU HU0302160A patent/HUP0302160A3/hu unknown
- 2001-11-19 AU AU2002215159A patent/AU2002215159A1/en not_active Abandoned
- 2001-11-19 DE DE60106968T patent/DE60106968T2/de not_active Expired - Fee Related
- 2001-11-19 EE EEP200300248A patent/EE200300248A/xx unknown
- 2001-11-19 DO DO2001000289A patent/DOP2001000289A/es unknown
- 2001-11-19 AP APAP/P/2001/002360A patent/AP2001002360A0/en unknown
- 2001-11-19 BR BR0115783-3A patent/BR0115783A/pt not_active IP Right Cessation
- 2001-11-19 SK SK619-2003A patent/SK6192003A3/sk unknown
- 2001-11-19 IL IL15570401A patent/IL155704A0/xx unknown
- 2001-11-19 AT AT01983739T patent/ATE281181T1/de not_active IP Right Cessation
- 2001-11-19 MX MXPA03004870A patent/MXPA03004870A/es unknown
- 2001-11-27 UY UY27042A patent/UY27042A1/es not_active Application Discontinuation
- 2001-11-28 AR ARP010105541A patent/AR031431A1/es unknown
- 2001-11-28 PE PE2001001191A patent/PE20020597A1/es not_active Application Discontinuation
- 2001-11-29 TN TNTNSN01169A patent/TNSN01169A1/fr unknown
- 2001-11-29 SV SV2001000751A patent/SV2003000751A/es unknown
- 2001-11-29 US US09/997,038 patent/US6544998B2/en not_active Expired - Fee Related
- 2001-11-30 PA PA20018534101A patent/PA8534101A1/es unknown
-
2003
- 2003-04-14 IS IS6786A patent/IS6786A/is unknown
- 2003-04-24 CR CR6964A patent/CR6964A/es not_active Application Discontinuation
- 2003-04-30 ZA ZA200303381A patent/ZA200303381B/en unknown
- 2003-05-07 BG BG107774A patent/BG107774A/xx unknown
- 2003-05-20 MA MA27165A patent/MA26964A1/fr unknown
- 2003-05-22 HR HR20030420A patent/HRP20030420A2/hr not_active Application Discontinuation
- 2003-05-27 EC EC2003004624A patent/ECSP034624A/es unknown
- 2003-05-28 NO NO20032441A patent/NO20032441L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200303381B (en) | Combination of gaba agonists and sorbitol dehydrogenase inhibitors. | |
| ZA200108039B (en) | Aminopyrimidines as sorbitol dehydrogenase inhibitors. | |
| DE60202452C5 (de) | Pyridazinonaldose reductase inhibitoren | |
| ES2974985T3 (es) | Inhibidores de FGFR y métodos de uso de los mismos | |
| CA2062792C (en) | Treatment of androgen-related diseases | |
| KR101835474B1 (ko) | 항바이러스 화합물 | |
| DE60107835T2 (de) | Medizinische zusammensetzungen zur förderung der aktivierung der eingeweide | |
| Grandison et al. | Inhibition of prolactin secretion by cholinergic drugs | |
| KR950703539A (ko) | 당뇨병 합병증 치료용 치환된 피리미딘(substituted pyrimidines for control or diabetic complications) | |
| DE202012013074U1 (de) | Zusammensetzungen zur Behandlung von HCV | |
| CA2061607A1 (en) | 1-biphenylimidazole derivatives, their preparation and their therapeutic use | |
| CA1331139C (en) | Medicaments for the treatment of cerebral apoplexy | |
| WO1994002150A1 (en) | Use of 1,3-dicyclopropymethyl-8-amino-xanthine for the treatment and prevention of type ii diabetes mellitus and obesity | |
| EP2555774A1 (de) | Arnzeimittelkombinationen enthaltend pde4-inhibitoren und ep4-rezeptor-antagonisten | |
| IE920385A1 (en) | Psoriasis treatment | |
| ZA200108174B (en) | Amine derivatives. | |
| CH683151A5 (de) | Antikonzeption bei weiblichen Primaten ohne Beeinflussung des menstruellen Zyklus. | |
| JP2009539997A5 (de) | ||
| DE69333362T3 (de) | Verwendung von angiotensin antagonisten (at1) zur verminderung des erkrankungs- und todesfallrisikos nach myokardinfarkt | |
| CA1230053A (en) | Gamma interferon - lymphotoxin synergism | |
| ZA200302229B (en) | Combination of statins and sorbitor dehydrogenase inhibitors. | |
| EP0532512B1 (de) | Verwendung von antagonisten des plättchen-aktivierenden faktors bei pruritus | |
| AU3079184A (en) | Triazolo(4,3-alpha)-pyrimidine derivatives | |
| ZA200307204B (en) | Combinations of aldose reductase inhibitors and cyclooxygenase-2-inhibitors. | |
| Campora et al. | The antiemetic efficacy of methylprednisolone compared with metoclopramide in outpatients receiving adjuvant CMF chemotherapy for breast cancer: A randomized trial |